Recombinant RSV live vaccine strain and the preparing method thereof
AssigneeSK Bioscience Co., Ltd.
InventorsKi-weon Seo, Eun-som Kim, Teawoo Kwon
Life of this patent
Estimating the term…
Abstract
The present invention provides a recombinant attenuated respiratory syncytial virus (RSV) comprising F protein of stabilized pre-fusion RSV, or comprising protein consisting of the amino acid sequence represented by SEQ ID NO: 2 or functional fragment thereof, and provides genome of the recombinant RSV and a recombinant vector comprising the genome. The recombinant attenuated RSV can be provided as a live vaccine strain which maintains infectability and has excellent safety and stability.
Claims14
A recombinant attenuated respiratory syncytial virus (RSV) comprising
- a nucleic acid encoding a chimeric vesicular stomatitis Indiana virus (VSV) G protein, wherein the chimeric VSV G protein consists of the amino acid sequence of SEQ ID NO:
- 2.
A recombinant attenuated respiratory syncytial virus (RSV) comprising a nucleic acid encoding a stabilized pre-fusion RSV F protein, wherein the stabilized pre-fusion RSV F protein has at least one mutation at a furin cleavage site of the F protein, and wherein amino acid residues RARR (SEQ ID NO:
- 38) corresponding to furin cleavage site II of the F protein at amino acid positions 106-109 of SEQ ID NO:
- 29 are modified to RPSK (SEQ ID NO:
- 39), or amino acid residues RKRR (SEQ ID NO:
- 40) corresponding to furin cleavage site I of the F protein at amino acid positions 133-136 of SEQ ID NO:
- 29 are substituted with RKRK (SEQ ID NO:
- 41).
Dependencies are inferred from the claim text.